American Society of Hirudotherapy

The comeback of hirudin--an old-established anticoagulant agent

Review published in Folia Haematol Int Mag Klin Morphol Blutforsch (1988)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewSalivary PharmacologyDrug DevelopmentMarkwardt F et al. · Folia Haematol Int Mag Klin Morphol Blutforsch, 1988

Abstract

Early studies dating back to 1884 revealed that extracts from medicinal leeches contain a substance which is able to prevent blood from clotting. Since our successful isolation of hirudin, the pure anticoagulant substance, in the late 1950s and its characterization as a selective thrombin inhibitor with polypeptide structure, hirudin preparations have been employed for diagnostic and scientific uses in haemostaseology. As early as 25 years ago we have shown in experimental pharmacotoxicological studies that hirudin is an anticoagulant of high quality. The antithrombotic effect of hirudin was demonstrated in several thrombosis models. But the clinical use of hirudin remained limited since it was not available in adequate amounts for therapeutic purposes. One hundred years after its discovery there is a renewed interest in this naturally occurring thrombin inhibitor. Advanced methods of peptide isolation and genetic engineering are about to provide sufficient quantities of hirudin in purified form. This prompted us to resume our investigations in hirudin and to represent new experimental and clinical pharmacological studies with natural hirudin prepared from medicinal leeches and genetically engineered recombinant hirudin, thus appreciating the comeback of hirudin into the focus of interest.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAmino Acid SequenceAnimalsHirudinsHumansMolecular Sequence DataThrombin

Summary

This review recounts how hirudin, the selective thrombin inhibitor isolated from medicinal leeches by the author's group in the late 1950s, is returning to prominence as advanced isolation and genetic engineering are about to supply sufficient quantities.

Why This Matters for Hirudotherapy

This article traces the history of hirudin from its 1884 discovery through its isolation in the late 1950s and characterization as a selective thrombin inhibitor with polypeptide structure, noting its use in diagnostic and scientific haemostaseology and its demonstrated antithrombotic effect in thrombosis models. Clinical use was historically limited by insufficient availability, but advanced methods of peptide isolation and genetic engineering are described as enabling adequate production quantities, prompting renewed interest. The article represents new experimental and clinical pharmacological studies with both natural hirudin from medicinal leeches and genetically engineered recombinant hirudin. Hirudin is an anticoagulant substance derived from medicinal leeches. However, the article's scope is limited to hirudin specifically rather than the full range of bioactive leech salivary molecules, and details of the represented studies are not elaborated in the abstract.

Citation

Reference (Vancouver style)

Markwardt F. The comeback of hirudin--an old-established anticoagulant agent. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1-2):10-23. PMID: 2459000

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.